Consensus and controversies regarding the treatment of rhabdomyosarcoma

Scott C. Borinstein, Diana Steppan, Masanori Hayashi, David M. Loeb, Michael S. Isakoff, Odion Binitie, Andrew S. Brohl, Julia A. Bridge, Mark Stavas, Eric T. Shinohara, William H. Meyer, Damon R. Reed, Lars M. Wagner

Research output: Contribution to journalReview articlepeer-review

62 Scopus citations


Optimal treatment of rhabdomyosarcoma (RMS) requires multidisciplinary approach, incorporating chemotherapy with local control. Although current therapies are built on cooperative group trials, a comprehensive standard of care to guide clinical decision making has been lacking, especially for relapsed patients. Therefore, we assembled a panel of pediatric and adolescent and young adult sarcoma experts to develop treatment guidelines for managing RMS and to identify areas in which further research is needed. We created algorithms incorporating evidence-based care for patients with RMS, emphasizing the importance of clinical trials and close integration of all specialties involved in the care of these patients.

Original languageEnglish (US)
Article numbere26809
JournalPediatric Blood and Cancer
Issue number2
StatePublished - Feb 2018


  • adolescent and young adult
  • chemotherapy
  • pediatric
  • rhabdomyosarcoma
  • sarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Consensus and controversies regarding the treatment of rhabdomyosarcoma'. Together they form a unique fingerprint.

Cite this